Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population

Twenty-eight-week results from the REALISTIC phase IIIb randomized trial: efficacy, safety and predictability of response to certolizumab pegol in a diverse rheumatoid arthritis population

Bibliographic Details
Main Authors: Weinblatt, Michael E., Fleischmann, Roy, van Vollenhoven, Ronald F., Emery, Paul, Huizinga, Tom WJ, Cutolo, Maurizio, van der Heijde, Désirée, Duncan, Benjamin, Davies, Owen, Luijtens, Kristel, Dougados, Maxime
Format: Online
Language:English
Published: BioMed Central 2015
Online Access:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644627/

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644627/

Similar Items